342 results about "Mother cells" patented technology

Methods, compositions and kits for determining the developmental potential of one or more embryos or pluripotent cells and / or the presence of chromosomal abnormalities in one or more embryos or pluripotent cells are provided. These methods, compositions and kits find use in identifying embryos and oocytes in vitro that are most useful in treating infertility in humans.

The invention provides a method of cloning a reproductive and respiratory syndrome resisting pig. The method comprises the following steps: transferring CRISPR / Cas9 targeting vectors and CD163 gene homologous recombination modification vectors into fibroblasts of a pig to obtain positive clone cells, wherein the seventh exon of the endogenous CD163 gene in the positive clone cells of the pig is replaced by the tenth exon of the CD163-L1 gene of human, so that the positive clone cells are incapable of mediating PRRSV invading; obtaining a clone embryo by adopting a somatic cell nucleus transfer technology by taking positive cells as nucleus transfer donor cells and oocytes as nucleus transfer recipient cells; and transferring the clone embryo into the uterus of the pig, and impregnating to obtain a cloned pig. The method provided by the invention is low in cost, the time of obtaining the homozygous pig is shortened greatly, the expression of the CD163 gene is not affected by gene editing, and a foundation is laid for the research into the gene function of large animals and the establishment of disease models on the basis of CRISPR / Cas9 mediated homologous recombination.

The invention belongs to the field of micro-organism animal cell line and relates to a human hepatoma cell line which can emit high-intensity red or green fluorescence and has high transferring ability of lung and lymph node metastasis, and a method for establishing the same. The method comprises the following steps: using the human hepatoma cell line HCCLM3 and HCCLM6 which have high transferring ability of the lung and lymph node metastasis as mother cells, performing cotransfection on plasmid DNA of 239 cells through slow virus packaging plasmids to obtain false slow virus particles by expressing red or green fluorescent protein genes through eucaryon, and infecting liver cancer cell strains of the mother cells to obtain the chromosome integrated hepatoma cell line which has high transferring ability of the lung and lymph node metastasis and can stably expressing the red or the green fluorescence. The human hepatoma cell line which has high transferring ability of the lung and lymph node metastasis in vitro can be applied to the tracer studies on tumor cells, the molecular mechanism studies on the recurrence and transferring of liver cancer, as well as the pre-clinical drug efficacy studies on new anti-tumor drugs, thus the human hepatoma cell line has wide application prospect.

The present invention provides methods to manipulate differentiation of a neuroblastoma cell line (IMR-32) such that predominant Nav expression is either Nav1.3 in IMR-32 cells exposed to retinoic acid or Nav1.7 in cells grown under non-differentiating conditions. The cells of the present invention are useful for the discovery of new compounds that modulate the function of either Nav1.3 and / or Nav1.7.

This invention discloses anti-recombinant alkaline fibroblast growth factor human-derived Fab antibody and its application. The antibody segment genome comprises: heavy chain Fd chain and light chain kappa chain. This invention utilizes phage surface display technique to successfully construct kappa chain and Fd chain genes of human-derived Fab antibody that can neutralize recombinant human bFGF or FGF-2. Functional neutralizing antibody that can specifically bind bFGF or FGF-2 is obtained in prokaryotic cells, yeast cells, insect cells and eukaryotic cells, which can be used to prepare antibody drugs that can diagnose and treat tumors, and inhibit kidney, liver and lung fibrosis. The bFGF or FGF-2 human-derived Fab antibody has high affinity and specificity, and can be directly used to develop antibody drugs.

The invention discloses an in-vitro maturation culture method for an oocyte mouse and a method for establishing a parthenogenetic embryonic stem cell line. In the in-vitro maturation culture method, an immature oocyte is cultured in a basic culture solution in which the HCG (human chorionic gonadotropin) and PMSG (pregnant mare serum gonadotropin) are added, and the maturation rate of the oocyte can reach more than 83 percent. In the method for establishing a parthenogenetic embryonic stem cell line, the parthenogenetic activation culture development is carried out on the mouse oocyte after in-vitro maturation culture to obtain the embryonic stem cell line; a hepatocyte obtained by the method has no immunogenicity, is simultaneously equivalent to a stem cell derived from a fertilized embryo on totipotency and has guiding significance for utilizing in-vitro maturation of the immature oocyte of a human and separating parthenogenetic embryonic stem cells. Aiming at the current conditionsof human ovum donation shortage, great discarding of clinical immature oocytes by an assisted reproductive technology, and the like, the two methods are combined to lay the foundation for developing and utilizing the in-vitro maturation culture of the immature oocyte of people and further researching the parthenogenetic embryo by utilizing an in-vitro mature ovum and separating the embryonic stemcells.

The invention discloses a Ni-Co-S loaded porous carbon material based on yeast cells. The preparation method comprises the following steps: preparing carbonized yeast cell porous carbon, carrying outhydrothermal reaction on the carbonized yeast cell porous carbon, cobalt nitrate, nickel nitrate and urea, and oxidizing and vulcanizing to obtain the material, the obtained material is of a core-shell structure, and cobalt and nickel elements are uniformly loaded on the surface of the yeast cell porous carbon in the form of NiCo2S4; wherein the shell-core structure is formed by carbonizing ellipsoidal single-cell fungal yeast, and carbonized yeast cells are of a hollow carbon sphere structure. The preparation method comprises the following steps: 1) preparing yeast cell porous carbon; 2) adsorbing cobalt-nickel metal ions by yeast cell porous carbon; and 3) vulcanizing the yeast cell porous carbon adsorbing the cobalt-nickel metal ions. When the material is used as a supercapacitor, the material is charged and discharged in a range of-0.2 to 0.5, and when the discharge current density is 1 A / g, the specific capacitance is 700 to 800 F / g. The invention has the following advantages: noharm is caused to human body; and the tolerance problem of the yeast cell metal salt solution is solved.

β-(1-6)-Glucanase treatment of glucan from yeast cells, pure or feed grade especially yeast from the family Saccharomyces and particularly Saccharomyces cerevisiae, provides a novel glucan product suitable for use in enhancing the stimulation of host animal immune systems. Solubilization of such yeast cell glucan is further disclosed to extend the usefulness of yeast cell glucan as an adjuvant.

The invention relates to the use of a laminin (LN) as a matrix for hepatic differentiation. The invention also relates to a method for inducing hepatic differentiation comprising the steps of: (i) providing a population of human pluripotent cells, (ii) culturing the population on a support coated with a laminin in a endoderm induction medium to produce a population of human DE cells, (iii) culturing said population of human DE cells on a support coated with a laminin in a hepatic induction medium to produce a population of human hepatoblasts-like cells, and (iv) optionally culturing said population of human hepatoblasts-like cells on a support coated with a laminin in a hepatic maturation medium to produce a population of human hepatocyte-like cells. The invention further relates to a population of human hepatoblasts-like cells or human fetal hepatocyte-like cells obtained by the method of the invention. The invention further relates to a population of human hepatoblasts-like cells expressing HNF4α and expressing substantially AFP for use in a method of treatment of the human body.

The present invention relates to a method of identifying a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) a yeast cell comprising: a) providing a mutated yeast cell comprising a deletion of at least one gene of the (PDH) by-pass, selected from the genes encoding the enzymes pyruvate decarboxylase (PDC), acetaldehyde dehydrogenase (ALD), and acetyl-CoA synthetase (ACS); b) transforming said mutated yeast cell with an expression vector comprising a heterologous nucleotide sequence encoding a candidate polypeptide having potential enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA; c) testing said recombinant mutated yeast cell for its ability to grow on minimal medium containing glucose as sole carbon source, and d) identifying said candidate polypeptide as a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) said yeast cell when growth of said cell is observed. The invention further relates to a method of producing a fermentation production such as butanol.